<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436993</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 14-67 [HS# 2015-1888]</org_study_id>
    <secondary_id>2015-1888</secondary_id>
    <nct_id>NCT02436993</nct_id>
  </id_info>
  <brief_title>Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab</brief_title>
  <official_title>A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase II is to study the efficacy and toxicity of carboplatin and&#xD;
      paclitaxel with pertuzumab and trastuzumab in HER2 positive and carboplatin and paclitaxel&#xD;
      with bevacizumab in HER2 negative in the neoadjuvant setting for the treatment of breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES The study component is to evaluate the treatment response and toxicity of the&#xD;
      protocol.&#xD;
&#xD;
      Objectives for treatment study component:&#xD;
&#xD;
      1.1 To estimate 2-year progression-free survival in patients with breast cancer with tumor&#xD;
      more than 1 cm and/or with clinically detected lymph node treated with neoadjuvant weekly&#xD;
      Carboplatin and Paclitaxel combined with Trastuzumab + Pertuzumab in HER2-positive disease or&#xD;
      with Bevacizumab in HER2-negative disease.&#xD;
&#xD;
      1.2 To measure the microscopic complete pathological response (pCR) rates defined as ypT0 or&#xD;
      ypTis tumors in patients treated with this regimen in the neoadjuvant setting.&#xD;
&#xD;
      1.3 To assess complete clinical response (cCR) rates after treatment by physical exam and&#xD;
      imaging tests (ultrasonography, mammography, or magnetic resonance imaging) clinical&#xD;
      objective response rate (by Response Evaluation Criteria In Solid Tumors (RECIST)) 1.4 To&#xD;
      determine the toxicity of this regimen. 1.5 To determine treatment adherence and delivered&#xD;
      dose intensity of this regimen.&#xD;
&#xD;
      1.6 To assess the correlation between pCR and cCR. 1.7 To determine the rate of breast&#xD;
      conservation following neoadjuvant therapy. 1.8 Determine treatment efficacy according to&#xD;
      subgroups defined according to stage and receptor status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression free survival in patients treated with weekly carboplatin and paclitaxel combined with either trastuzumab and pertuzumab for HER2-positive patients or bevacizumab for HER2-negative patients in the neoadjuvant setting</measure>
    <time_frame>2 years</time_frame>
    <description>Progression of disease-A new lesion or a greater than or equal to 25% increase in the product of the largest perpendicular diameters of any one lesion on clinical exam or by U/S or MRI Survival-from date of registration to date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response rates</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical complete response (cCR)-Normal breast on physical exam. No mass, no thickening, no erythema, no peau d'orange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response rates</measure>
    <time_frame>2 years</time_frame>
    <description>Pathologic complete response (pCR)-No histologic evidence of microscopic invasive tumor at the primary tumor site in the surgical specimen (ypT0 or DCis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of toxicities in Carboplatin+Paclitaxel+Bevacizumab (HER2) arm</measure>
    <time_frame>Up to 42 days after discontinued treatment</time_frame>
    <description>This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of toxicities in Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</measure>
    <time_frame>Up to 42 days after discontinued treatment</time_frame>
    <description>This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 for toxicity and Adverse Event reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carboplatin+Paclitaxel+Bevacizumab (HER2-)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses</description>
    <arm_group_label>Carboplatin+Paclitaxel+Bevacizumab (HER2-)</arm_group_label>
    <arm_group_label>Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m^2 IV over 1-3 hours weekly for 12 doses</description>
    <arm_group_label>Carboplatin+Paclitaxel+Bevacizumab (HER2-)</arm_group_label>
    <arm_group_label>Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses</description>
    <arm_group_label>Carboplatin+Paclitaxel+Bevacizumab (HER2-)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses</description>
    <arm_group_label>Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses</description>
    <arm_group_label>Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven unilateral or bilateral primary breast carcinoma. (In case of&#xD;
             bilateral cancer, the investigator has to decide prospectively which side will be&#xD;
             evaluated for the primary endpoint.)&#xD;
&#xD;
          2. Tumor size is clinically at least 1 cm in greatest diameter (palpable or by imaging)&#xD;
             and/or with involved lymph node. In case of inflammatory disease, the extent of&#xD;
             inflammation may be the measurable lesion.&#xD;
&#xD;
          3. Documentation of inflammatory breast cancer&#xD;
&#xD;
          4. Woman age &gt; or = 18&#xD;
&#xD;
          5. Performance status of 0-2 by Eastern Cooperative Oncology Group (ECOG) criteria&#xD;
&#xD;
          6. Known HER2 status&#xD;
&#xD;
          7. Normal cardiac function must be documented within 90 days prior to registration either&#xD;
             via an ECHO or MUGA or per physician's review of symptoms and medical history. If an&#xD;
             ECHO is performed as standard of care, the ejection fraction must be above the normal&#xD;
             limit of the institution.. If not available in the medical chart, the ECHOs or MUGAs&#xD;
             are not required to be repeated for research purposes.&#xD;
&#xD;
             a. Date of Echo or multigated acquisition (MUGA) (within 90 days) if performed&#xD;
&#xD;
          8. Staging work-up prior to registration&#xD;
&#xD;
               1. Date of physical examination (within 90 days)&#xD;
&#xD;
               2. Date of bilateral mammogram (within 90 days)&#xD;
&#xD;
               3. Date of breast ultrasound (within 90 days)&#xD;
&#xD;
               4. Date of MRI breast (within 30 days)&#xD;
&#xD;
               5. Chest X-ray or CT- Chest or CT/PET Scan that includes the Chest may be done at&#xD;
                  physician's discretion (within 90 days). If not available in the medical chart,&#xD;
                  the Chest X-ray or CT- Chest or CT/PET Scan that includes the Chest is not&#xD;
                  required to be repeated for research purposes.&#xD;
&#xD;
               6. Other tests as clinically indicated&#xD;
&#xD;
          9. Laboratory requirements:&#xD;
&#xD;
               1. Hematology:&#xD;
&#xD;
                    -  Absolute Neutrophil Count (ANC) ≥ 1,500/μl&#xD;
&#xD;
                    -  Platelets ≥ 100,000/μl&#xD;
&#xD;
               2. Hepatic Function&#xD;
&#xD;
                    -  Total Bilirubin &lt;1x upper limit of normal (ULN)&#xD;
&#xD;
                    -  aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2x ULN&#xD;
&#xD;
               3. Renal Function&#xD;
&#xD;
                  - Creatinine &lt;1.5x ULN&#xD;
&#xD;
               4. Proteinuria&#xD;
&#xD;
                  - Random urine total protein &lt;100mg/dL. Urine Protein Creatinine (UPC) ratio &lt;2g&#xD;
&#xD;
               5. Negative pregnancy test for women of childbearing potential within 14 days prior&#xD;
                  to registration.&#xD;
&#xD;
         10. All patients must be informed of the investigational nature of this study and must&#xD;
             sign and give written informed consent in accordance with institutional and federal&#xD;
             guidelines.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         11. Evidence of distant metastasis. If radiographic suspicion of distant metastatic site,&#xD;
             a negative biopsy must be available in the medical record. If not available in the&#xD;
             medical record, the subject may be included and a confirmatory biopsy is not required&#xD;
             to be performed for research purposes.&#xD;
&#xD;
         12. Known or suspected congestive heart failure, angina pectoris requiring antianginal&#xD;
             medication, or other clinically significant cardiac condition.&#xD;
&#xD;
         13. Pregnant or nursing women may not participate due to the possibility of harm to fetus&#xD;
             or nursing infants from this treatment regimen. Women of childbearing potential may&#xD;
             not participate unless they have agreed to use an adequate contraceptive method&#xD;
             throughout study treatment and for one month after completion of treatment.&#xD;
&#xD;
         14. Male patients&#xD;
&#xD;
         15. Pre-existing peripheral neuropathy of severity grade ≥ 2 (limiting instrumental&#xD;
             activities of daily living).&#xD;
&#xD;
         16. Incomplete wound healing.&#xD;
&#xD;
         17. Active and significant bleeding&#xD;
&#xD;
         18. Known allergy, hypersensitivity or prior infusion reaction to one or more of the&#xD;
             therapies incorporated into this treatment protocol.&#xD;
&#xD;
         19. Bone marrow depression or hematologic parameters in the range that would increase the&#xD;
             risk for severe bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UC Irvine Health Chao Family Comprehensive Cancer Center</last_name>
    <phone>1-877-UC-STUDY</phone>
    <email>UCstudy@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Family Comprehensive Cancer Center University of California, Irvine Medical Center</last_name>
      <phone>877-827-8839</phone>
      <email>UCstudy@uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant Treatment</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Pertuzumab</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

